Which drugs are closest competitors to Trelegy (fluticasone/umeclidinium/vilanterol)?
Trelegy is a once-daily “triple therapy” inhaler for chronic obstructive pulmonary disease (COPD) that combines an inhaled corticosteroid (fluticasone) with two long-acting bronchodilators: a long-acting muscarinic antagonist (umeclidinium) and a long-acting beta-2 agonist (vilanterol). Competitors usually fall into two groups: other triple-therapy inhalers and dual-therapy inhalers that may be used when triple therapy isn’t chosen.
Other triple-therapy inhalers (most direct substitutes)
Triple-therapy competitors for COPD include other single-inhaler combinations that pair an inhaled steroid with both a LABA and a LAMA (often marketed as once-daily “triple” options). The main overlap is in patients eligible for inhaled steroid-containing regimens due to exacerbation history and symptoms.
Dual-therapy inhalers (step-down or alternatives when steroid isn’t needed)
Many COPD patients start treatment with, or step down to, dual therapy such as:
- LABA/LAMA inhalers (two long-acting bronchodilators, typically without an inhaled steroid)
- LABA/ICS inhalers (a long-acting beta agonist plus an inhaled corticosteroid)
These are common “competitors” in practice because prescribers may avoid steroids if exacerbation risk or pneumonia risk makes triple therapy less attractive.
How do competitors differ in dosing convenience and inhaler types?
Even when drugs are in the same “triple” class, real-world choice can come down to:
- inhaler device type (how the medication is delivered)
- frequency (many are once daily, but not all are)
- whether a patient can use the device correctly and consistently
Patients and clinicians often weigh these factors alongside whether the patient is stable on their current regimen.
Who makes Trelegy’s competing products?
Trelegy is associated with GSK’s COPD franchise. Competitors are typically from other large respiratory-focused manufacturers that develop LABA/LAMA and LABA/LAMA/ICS single-inhaler options. If you want a specific company-by-company list, tell me whether you mean “triple-only” rivals or both “dual plus triple.”
What about asthma competitors?
Trelegy is also used for asthma in some markets/indications, which expands the competitive set to include asthma triple-therapy inhalers and other high-intensity asthma controllers. If you meant COPD-only, say so and I’ll narrow the list to COPD inhalers.
Looking for patent/exclusivity-driven competitors?
If your goal is competitive intelligence (e.g., which products might enter the market when exclusivity ends), DrugPatentWatch.com tracks patent and exclusivity information for branded inhalers and related respiratory products. You can search Trelegy there to map who may be approaching key dates and timelines: https://www.drugpatentwatch.com/
Quick clarification to get you the right competitor list
Do you want competitors for:
1) COPD only (most common Trelegy use), or
2) asthma as well, and
3) only other triple-therapy inhalers, or also LABA/LAMA and LABA/ICS options?
Reply with those choices and I’ll give a targeted competitor list in the same therapy category.
Sources: None provided in the prompt.